Study of Chemotherapy Effects on Urinary Biomarkers and Bladder Function in Childhood Cancer Survivors Aged 5 to 13

What this Trial Is About

Researchers are studying the effects of the chemotherapies vincristine and doxorubicin on bladder function and urine composition in children who survived cancer. They aim to understand if these treatments are linked to bladder dysfunction symptoms using a survey called the Dysfunctional Voiding Symptom Score DVSS. The study also compares non-invasive bladder tests and urine biomarkers between children with and without bladder dysfunction. Participants are childhood cancer survivors aged 5 to 13 years who received vincristine andor doxorubicin chemotherapy at least one year before joining the study. They are grouped based on bladder dysfunction symptoms measured by DVSS, separated by gender and symptom severity. The study uses non-invasive urodynamic tests to evaluate urinary flow and urine proteomic screening to analyze proteins and peptides related to bladder health. During the study, children complete the DVSS survey, undergo non-invasive bladder function testing, and provide urine samples for biomarker analysis. Researchers will measure differences in bladder test patterns, urine residual volumes after voiding, urine flow rates, and urinary biomarkers over a 13-month period. This approach helps understand bladder health changes after chemotherapy in childhood cancer survivors.

Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children